Citadel Advisors
CRBU icon

Citadel Advisors’s Caribou Biosciences CRBU Stock Holding History

Citadel Advisors’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$302K Sell
159,033
-356,396
-69% -$612K ﹤0.01% 10461
2025
Q4 		$820K Buy
515,429
+250,306
+94% +$525K ﹤0.01% 7852
2025
Q3 		$618K Buy
265,123
+24,904
+10% +$47K ﹤0.01% 8611
2025
Q2 		$303K Buy
+240,219
New +$236K ﹤0.01% 9807
2024
Q4 		– Sell
-64,458
Closed -$130K – 14623
2024
Q3 		$126K Buy
64,458
+1,968
+3% +$4.03K ﹤0.01% 10805
2024
Q2 		$102K Sell
62,490
-464,424
-88% -$1.48M ﹤0.01% 10882
2024
Q1 		$2.71M Buy
+526,914
New +$3.25M ﹤0.01% 4964
2023
Q4 		– Sell
-2,989
Closed -$14.8K – 14366
2023
Q3 		$14.3K Buy
2,989
+868
+41% +$5.38K ﹤0.01% 12881
2023
Q2 		$9.01K Sell
2,121
-280,729
-99% -$1.26M ﹤0.01% 13282
2023
Q1 		$1.5M Buy
282,850
+244,955
+646% +$1.53M ﹤0.01% 5908
2022
Q4 		$238K Buy
37,895
+9,964
+36% +$88.7K ﹤0.01% 9800
2022
Q3 		$295K Sell
27,931
-38,044
-58% -$354K ﹤0.01% 9618
2022
Q2 		$358K Sell
65,975
-291,526
-82% -$2.23M ﹤0.01% 9408
2022
Q1 		$3.28M Buy
357,501
+206,391
+137% +$2.17M ﹤0.01% 4998
2021
Q4 		$2.28M Buy
+151,110
New +$2.94M ﹤0.01% 5945

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's CRBU Position: Q1 2026 in Review

Citadel Advisors reduced its Caribou Biosciences (CRBU) stake by 69% in Q1 2026, selling an estimated $612K and leaving 159,033 shares worth $302K. The position accounts for ﹤0.01% of the portfolio, ranked #10461.

Citadel Advisors first reported a position in CRBU in Q4 2021 and has held it in 15 quarters since. The position peaked at $3.28M in Q1 2022. 137 funds tracked by Wall St. Rank hold CRBU as of Q1 2026.

  • Citadel Advisors held 159,033 shares of Caribou Biosciences worth $302K as of Q1 2026.
  • Citadel Advisors sold 356,396 Caribou Biosciences shares in Q1 2026, an estimated $612K.
  • Caribou Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10461 holding.
  • Citadel Advisors first reported a position in Caribou Biosciences in Q4 2021 and has held it in 15 quarters since.
  • Citadel Advisors's Caribou Biosciences position peaked at $3.28M in Q1 2022.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.